| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/16/2002 | US6420421 Alkyl-dimethyl-benzyl or ethylbenzyl ammonium chloride mixture and bis(tri-n-butyltin)oxide; used to treat viral, bacterial and fungal infections in mammals and avians |
| 07/16/2002 | US6420346 Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| 07/16/2002 | US6420176 Composition for delivering DNA into antigen presenting cells |
| 07/16/2002 | US6420175 Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| 07/16/2002 | US6420172 Method for inducing tumor immunity |
| 07/16/2002 | US6420161 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides |
| 07/16/2002 | US6420160 Expression vector for use in immunotherapy and gene therapy |
| 07/16/2002 | US6420155 Polypeptide for use in the treatment of cancer and atherosclerosis |
| 07/16/2002 | US6420141 Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids |
| 07/16/2002 | US6420139 Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| 07/16/2002 | US6420135 Streptococcus pneumoniae polynucleotides and sequences |
| 07/16/2002 | US6420134 Vaccines for nontypable haemophilus influenzae |
| 07/16/2002 | US6420126 Tumor specific internalizing antigens and methods for targeting therapeutic agents |
| 07/16/2002 | US6419933 Genetic engineered polypeptide |
| 07/16/2002 | US6419932 Antigen of hybrid M protein and carrier for Group A streptococccal vaccine |
| 07/16/2002 | US6419931 Compositions and methods for eliciting CTL immunity |
| 07/16/2002 | US6419930 Pharmacological composition having blood pressure reductive activity |
| 07/16/2002 | US6419929 Genetic engineering |
| 07/16/2002 | US6419927 Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
| 07/16/2002 | US6419926 Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers |
| 07/16/2002 | US6419925 Toxoplasma gondii antigens, the preparation thereof and the use thereof |
| 07/16/2002 | US6419923 Filariid nematode cysteine protease proteins, and uses thereof |
| 07/16/2002 | US6419919 Method for the augmentation of gene expression |
| 07/16/2002 | US6419846 Determining endpoint in etching processes using principal components analysis of optical emission spectra |
| 07/16/2002 | CA2131383C Wound healing and treatment of fibrotic disorders |
| 07/16/2002 | CA2095926C Anti-human milk fat globule humanised antibodies |
| 07/16/2002 | CA2090009C Methods for inhibiting rejection of transplanted tissue |
| 07/16/2002 | CA2052392C Extract from ginkgo biloba leaves, in particular for intravenous injection or infusion, a method of preparation of the extract and ampoule preparations containing the extract |
| 07/16/2002 | CA2024063C Antibodies directed against nerve growth factor-like peptides |
| 07/16/2002 | CA1341377C Composition and method for acceleration of clot lysis |
| 07/11/2002 | WO2002054073A2 Latent human tuberculosis model, diagnostic antigens, and methods of use |
| 07/11/2002 | WO2002053775A2 Identification of genetic determinants of polymorphic cyp3a5 expression |
| 07/11/2002 | WO2002053761A2 Recombinant protective protein from $i(streptococcus pneumoniae) |
| 07/11/2002 | WO2002053757A1 Hiv-like particles and the use thereof |
| 07/11/2002 | WO2002053742A2 Proteins and nucleic acids encoding same |
| 07/11/2002 | WO2002053737A1 Nf-kb activating gene |
| 07/11/2002 | WO2002053733A2 Regulation of human b7-h2 protein |
| 07/11/2002 | WO2002053700A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 07/11/2002 | WO2002053596A2 Antibodies to insulin-like growth factor i receptor |
| 07/11/2002 | WO2002053595A1 Group 2 allergen specific ige-fabs and igg molecules and use thereof |
| 07/11/2002 | WO2002053588A2 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia psittaci |
| 07/11/2002 | WO2002053587A2 Polypeptide inducing hiv-neutralising antibodies |
| 07/11/2002 | WO2002053288A2 A method for the manufacture of compositions containing low concentrations of salts |
| 07/11/2002 | WO2002053189A2 Immunogenic complex |
| 07/11/2002 | WO2002053185A2 Anti-inflammatory use of polycationic compounds |
| 07/11/2002 | WO2002053184A2 Uses for polycationic compounds as vaccine adjuvants |
| 07/11/2002 | WO2002053183A1 Hantavirus vaccin with adjuvant |
| 07/11/2002 | WO2002053182A1 Chimeric t helper-b cell peptide vaccine for japanese encephalitis virus |
| 07/11/2002 | WO2002053181A1 Enterohemorragic escherichia coli vaccine |
| 07/11/2002 | WO2002053180A2 Immunizing compositions and methods of use |
| 07/11/2002 | WO2002053179A1 The method for the production of the egg containing anti-pathogenic bacteria specific antibodies (igy) and the yogurt and ice cream contaiing the igy |
| 07/11/2002 | WO2002053178A2 Immunogenic complex comprising ribosomes |
| 07/11/2002 | WO2002053177A2 Agents and methods for treating pain |
| 07/11/2002 | WO2002053176A2 An autologous anti-cancer vaccine |
| 07/11/2002 | WO2002053175A2 Use of botulinum toxin for treatment of articular pathologies |
| 07/11/2002 | WO2002053174A2 Controlled release pharmaceutical systems |
| 07/11/2002 | WO2002053171A2 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity |
| 07/11/2002 | WO2002053168A2 Sterilising pill |
| 07/11/2002 | WO2002053166A1 Use of tinospora extract in the treatment of immune system-modulated disorders |
| 07/11/2002 | WO2002053106A2 Autoantigen composition |
| 07/11/2002 | WO2002053092A2 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 07/11/2002 | WO2002034119A3 Vaccine immunotherapy for immune suppressed patients |
| 07/11/2002 | WO2002030970A3 Human histone deacetylase gene |
| 07/11/2002 | WO2002028480A3 Methods of therapy for b-cell malignancies |
| 07/11/2002 | WO2002022783A3 Liver gene expression associated with the inhibition of hbv replication or transcription |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002016421A8 Altered ospa of borrelia burgdorferi |
| 07/11/2002 | WO2002014511A3 Regulation of human p2y1-like g protein-coupled receptor |
| 07/11/2002 | WO2002013857A3 A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| 07/11/2002 | WO2002008456A8 Method for identifying metastatic tumor cells |
| 07/11/2002 | WO2002000862A3 32447, a novel human acyltransferase and uses thereof |
| 07/11/2002 | WO2001085207A3 Modulation of antigen processing using phagocytic cells |
| 07/11/2002 | WO2001079274A3 Tuberculosis antigens and methods of use thereof |
| 07/11/2002 | WO2001046383A9 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001036473A3 Human g protein-coupled receptors |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001030392A3 Delivery of proteins across polar epithelial cell layers |
| 07/11/2002 | WO2001025438A3 Ifn-alpha homologues |
| 07/11/2002 | WO2001025273A3 Compositions and methods for wt1 specific immunotherapy |
| 07/11/2002 | WO2001021213A3 Inhibition of secretion from non-neuronal cells |
| 07/11/2002 | WO2001012816A3 Porcine endovirus gag and env and diagnostic uses thereof |
| 07/11/2002 | WO2001012220A9 Non-immunosuppressant hiv tat |
| 07/11/2002 | WO2001011086A9 Methods of screening for angiogenesis modulators |
| 07/11/2002 | WO2000077486A3 Compositions and methods for detecting treponema pallidum |
| 07/11/2002 | WO2000073321A9 Human tumor necrosis factor receptor tr10 |
| 07/11/2002 | WO2000073263A9 Cytofectin dimers and methods of use thereof |
| 07/11/2002 | WO2000066179A9 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 07/11/2002 | WO2000064488A9 Somatic transgene immunization and related methods |
| 07/11/2002 | WO2000063438A3 Method of classifying a thyroid carcinoma using differential gene expression |
| 07/11/2002 | WO2000062067A9 Novel transduction molecules and methods for using same |
| 07/11/2002 | WO2000061747A9 Clasp-2 transmembrane proteins |
| 07/11/2002 | US20020091246 Dendritic cell co-stimulatory molecules |
| 07/11/2002 | US20020091244 Nucleotide sequences for use in diagnosis and treatment of cancer and immunological disorders |
| 07/11/2002 | US20020091240 Humanized antibodies to gamma-interferon |
| 07/11/2002 | US20020091236 Nucleotide sequences coding preferential polypeptide for use in detection of bactericides |
| 07/11/2002 | US20020091234 Adjuvant for enhancing immune response to preferential immunogen |
| 07/11/2002 | US20020091098 Also administering to the subject an effective amount of an mda-7 protein. |
| 07/11/2002 | US20020091097 Nucleic acids for the prevention and treatment of sexually transmitted diseases |
| 07/11/2002 | US20020091096 Nucleic acid, including DNA, immunization against disease caused by infection by a strain of Chlamydia employing a vector, containing a nucleotide sequence encoding a lorf2 protein of a strain of Chlamydia |